Go to
current issue
-
FDA approves l-amino acid decarboxylase deficiency gene therapy Nat. Rev. Drug. Disc. (IF 122.7) Pub Date : 2024-11-15
Discover the world’s best science and medicine | Nature.com
-
Senescence as a therapeutic target in cancer and age-related diseases Nat. Rev. Drug. Disc. (IF 122.7) Pub Date : 2024-11-15 Domhnall McHugh, Imanol Durán, Jesús Gil
-
DNA damage response inhibitors in cancer therapy: lessons from the past, current status and future implications Nat. Rev. Drug. Disc. (IF 122.7) Pub Date : 2024-11-12 Yvette Drew, Frank T Zenke, Nicola J Curtin
-
Benchmarking recruitment rates for phase III trials Nat. Rev. Drug. Disc. (IF 122.7) Pub Date : 2024-11-08
Discover the world’s best science and medicine | Nature.com
-
Antimalarial drug hits cardiac fibrosis Nat. Rev. Drug. Disc. (IF 122.7) Pub Date : 2024-11-05
Discover the world’s best science and medicine | Nature.com
-
Lundbeck pays US$2.6 billion for Longboard and its lead epilepsy drug Nat. Rev. Drug. Disc. (IF 122.7) Pub Date : 2024-11-05
Discover the world’s best science and medicine | Nature.com
-
JAK inhibition combats adverse skin reaction Nat. Rev. Drug. Disc. (IF 122.7) Pub Date : 2024-11-05
Discover the world’s best science and medicine | Nature.com
-
The state-of-the-art of N-of-1 therapies and the IRDiRC N-of-1 development roadmap Nat. Rev. Drug. Disc. (IF 122.7) Pub Date : 2024-11-04 Anneliene H. Jonker, Elena-Alexandra Tataru, Holm Graessner, David Dimmock, Adam Jaffe, Gareth Baynam, James Davies, Shruti Mitkus, Oxana Iliach, Rich Horgan, Erika F. Augustine, Alison Bateman-House, Anna Maria Gerdina Pasmooij, Tim Yu, Matthis Synofzik, Julie Douville, Larissa Lapteva, Philip John Brooks, Daniel O’Connor, Annemieke Aartsma-Rus
-
Anti-tau antibody stumbles in phase II Alzheimer trial Nat. Rev. Drug. Disc. (IF 122.7) Pub Date : 2024-11-01
Discover the world’s best science and medicine | Nature.com
-
Bivalent molecules unmute silenced genes Nat. Rev. Drug. Disc. (IF 122.7) Pub Date : 2024-11-01
Discover the world’s best science and medicine | Nature.com
-
How GLP-1 went from being a hard-to-handle hormone to a blockbuster success Nat. Rev. Drug. Disc. (IF 122.7) Pub Date : 2024-11-01
Lotte Bjerre Knudsen, chief scientific advisor in research and early development at Novo Nordisk, discusses the past and future of GLP-1s and related anti-obesity drugs.
-
FDA approves first anti-TFPI antibody for haemophilia A and B Nat. Rev. Drug. Disc. (IF 122.7) Pub Date : 2024-10-30
Discover the world’s best science and medicine | Nature.com
-
FDA approves PI3Kα inhibitor that does double duty as a degrader Nat. Rev. Drug. Disc. (IF 122.7) Pub Date : 2024-10-30
Discover the world’s best science and medicine | Nature.com
-
Multivalent vaccine tackles C. difficile Nat. Rev. Drug. Disc. (IF 122.7) Pub Date : 2024-10-30
Discover the world’s best science and medicine | Nature.com
-
Antibody vanquishes SARS-CoV-2 variants Nat. Rev. Drug. Disc. (IF 122.7) Pub Date : 2024-10-29
Discover the world’s best science and medicine | Nature.com
-
Glucose-sensitive insulin protects against hypoglycaemia Nat. Rev. Drug. Disc. (IF 122.7) Pub Date : 2024-10-28
Discover the world’s best science and medicine | Nature.com
-
Targeting the TNF and TNFR superfamilies in autoimmune disease and cancer Nat. Rev. Drug. Disc. (IF 122.7) Pub Date : 2024-10-24 Michael Croft, Shahram Salek-Ardakani, Carl F. Ware
-
FDA approves first claudin-18.2-targeted antibody for gastric cancer Nat. Rev. Drug. Disc. (IF 122.7) Pub Date : 2024-10-22
Discover the world’s best science and medicine | Nature.com
-
Advanced technologies for the development of infectious disease vaccines Nat. Rev. Drug. Disc. (IF 122.7) Pub Date : 2024-10-21 Akash Gupta, Arnab Rudra, Kaelan Reed, Robert Langer, Daniel G. Anderson
-
Immunogenicity risk assessment and mitigation for engineered antibody and protein therapeutics Nat. Rev. Drug. Disc. (IF 122.7) Pub Date : 2024-10-18 Paul J. Carter, Valerie Quarmby
-
TLK2: a target for cancer and viral latency Nat. Rev. Drug. Disc. (IF 122.7) Pub Date : 2024-10-17
Discover the world’s best science and medicine | Nature.com
-
New eyes on the infectious disease prize Nat. Rev. Drug. Disc. (IF 122.7) Pub Date : 2024-10-15
Jeanne Marrazzo, the director of the NIAID, discusses post-COVID pandemic preparedness, H5N1 avian flu and the tension between infectious disease protection versus profit.
-
Protein degraders push into novel target space Nat. Rev. Drug. Disc. (IF 122.7) Pub Date : 2024-10-14
Clinic-ready molecular glues and heterobifunctional PROTAC drugs are taking targeted protein degradation into uncharted territory.
-
Reply to ‘Bayesian approaches in drug development: continuing the virtuous cycle’ Nat. Rev. Drug. Disc. (IF 122.7) Pub Date : 2024-10-10 Stephen J. Ruberg
We are thankful that Igl and Constant1 are joining the creation of the virtuous cycle for the use of Bayesian approaches in clinical trials. Their comments help to expand the considerations from the original paper2 and bring additional perspectives to bear on Bayesian approaches. We are in general agreement with their Correspondence. We will make a few additional comments on topics in the order they
-
Bayesian approaches in drug development: continuing the virtuous cycle Nat. Rev. Drug. Disc. (IF 122.7) Pub Date : 2024-10-10 Wilmar Igl, John Constant
Ruberg et al. recently published an article with the aim of starting a virtuous cycle in the use of Bayesian approaches in drug development (Nat. Rev. Drug Discov. 22, 235–250; 2023)1. Here, we would like to extend important arguments of their article and add recommendations for using Bayesian statistics2.
-
FDA new drug approvals in Q3 2024 Nat. Rev. Drug. Disc. (IF 122.7) Pub Date : 2024-10-10
Discover the world’s best science and medicine | Nature.com
-
Tumour cells get a dendritic cell makeover Nat. Rev. Drug. Disc. (IF 122.7) Pub Date : 2024-10-08
Discover the world’s best science and medicine | Nature.com
-
mRNA vaccines for infectious diseases — advances, challenges and opportunities Nat. Rev. Drug. Disc. (IF 122.7) Pub Date : 2024-10-04 Norbert Pardi, Florian Krammer
-
A viral–lipid hybrid delivery system for genetic therapies Nat. Rev. Drug. Disc. (IF 122.7) Pub Date : 2024-10-03
Discover the world’s best science and medicine | Nature.com
-
Two decades of new drug approvals in Japan Nat. Rev. Drug. Disc. (IF 122.7) Pub Date : 2024-10-02
Discover the world’s best science and medicine | Nature.com
-
FDA approves first monoclonal antibody for COPD Nat. Rev. Drug. Disc. (IF 122.7) Pub Date : 2024-10-01
Discover the world’s best science and medicine | Nature.com
-
Therapeutic targeting of senescent cells in the CNS Nat. Rev. Drug. Disc. (IF 122.7) Pub Date : 2024-09-30 Markus Riessland, Methodios Ximerakis, Andrew A. Jarjour, Bin Zhang, Miranda E. Orr
-
FDA approves first two drugs for rare Niemann–Pick disease Nat. Rev. Drug. Disc. (IF 122.7) Pub Date : 2024-09-27
Discover the world’s best science and medicine | Nature.com
-
Targeting fibrin in COVID-19 Nat. Rev. Drug. Disc. (IF 122.7) Pub Date : 2024-09-27
Discover the world’s best science and medicine | Nature.com
-
Identifying antimicrobials in the human microbiome Nat. Rev. Drug. Disc. (IF 122.7) Pub Date : 2024-09-27
Discover the world’s best science and medicine | Nature.com
-
Targeting undruggable GTPases Nat. Rev. Drug. Disc. (IF 122.7) Pub Date : 2024-09-27
Discover the world’s best science and medicine | Nature.com
-
Targeting the kynurenine pathway Nat. Rev. Drug. Disc. (IF 122.7) Pub Date : 2024-09-27
Discover the world’s best science and medicine | Nature.com
-
FDA approves first schizophrenia drug with new mechanism of action since 1950s Nat. Rev. Drug. Disc. (IF 122.7) Pub Date : 2024-09-26
Discover the world’s best science and medicine | Nature.com
-
The benefits of translating biomedical research at drug discovery institutes Nat. Rev. Drug. Disc. (IF 122.7) Pub Date : 2024-09-26 David J. Huggins, Jonathan Baell, Paul E. Brennan, Alex Burgin, Duncan E. Scott
Drug discovery institutes comprised of experienced drug discovery scientists collaborating with fundamental biomedical researchers provide solutions to many of the challenges in translating biomedical research.
-
Targeting neurofibrosis reverses metabolic dysfunction Nat. Rev. Drug. Disc. (IF 122.7) Pub Date : 2024-09-25
Discover the world’s best science and medicine | Nature.com
-
A tale of two ecosystems: the biopharma landscape in China and India Nat. Rev. Drug. Disc. (IF 122.7) Pub Date : 2024-09-25
Discover the world’s best science and medicine | Nature.com
-
Agonist antibody lowers blood pressure Nat. Rev. Drug. Disc. (IF 122.7) Pub Date : 2024-09-23
Discover the world’s best science and medicine | Nature.com
-
The AMR Accelerator: from individual organizations to efficient antibiotic development partnerships Nat. Rev. Drug. Disc. (IF 122.7) Pub Date : 2024-09-23 Josepine Fernow, Marie Olliver, William Couet, Sophie Lagrange, Meindert H. Lamers, Ole F. Olesen, Kristina Orrling, Michel Pieren, Derek J. Sloan, Juan José Vaquero, Timothy J. Miles, Anders Karlén
The AMR Accelerator is an Innovative Medicines Initiative programme integrating nine projects with the shared goal of progressing the development of new antibiotics and building antimicrobial resistance research capability. Five years in, we reflect on the programme’s value, results and key challenge: ensuring the sustainability of assets, infrastructures and expertise.
-
Publisher Correction: Strategies to therapeutically modulate cytokine action Nat. Rev. Drug. Disc. (IF 122.7) Pub Date : 2024-09-20 Warren J. Leonard, Jian-Xin Lin
Correction to: Nature Reviews Drug Discovery https://doi.org/10.1038/s41573-023-00746-x, published online 4 August 2023.
-
In vivo CAR T cells move into clinical trials Nat. Rev. Drug. Disc. (IF 122.7) Pub Date : 2024-09-16
Drug developers want to reprogramme immune cells directly in the body, opening up new gene therapy frontiers in cancer and autoimmunity.
-
Author Correction: Antimalarial drug discovery: progress and approaches Nat. Rev. Drug. Disc. (IF 122.7) Pub Date : 2024-09-13 Jair L. Siqueira-Neto, Kathryn J. Wicht, Kelly Chibale, Jeremy N. Burrows, David A. Fidock, Elizabeth A. Winzeler
Correction to: Nature Reviews Drug Discovery https://doi.org/10.1038/s41573-023-00772-9, published online 31 August 2023.
-
Creating an AI-first drug discovery engine Nat. Rev. Drug. Disc. (IF 122.7) Pub Date : 2024-09-13
Najat Khan — Chief R&D Officer and Chief Commercial Officer at Recursion — discusses the proposed merger of Recursion and Exscientia.
-
Targeting cytokine networks in neuroinflammatory diseases Nat. Rev. Drug. Disc. (IF 122.7) Pub Date : 2024-09-11 Burkhard Becher, Tobias Derfuss, Roland Liblau
-
Upcoming market catalysts in Q4 2024 Nat. Rev. Drug. Disc. (IF 122.7) Pub Date : 2024-09-10
Discover the world’s best science and medicine | Nature.com
-
Neurons give metastatic cells a push Nat. Rev. Drug. Disc. (IF 122.7) Pub Date : 2024-09-09
Discover the world’s best science and medicine | Nature.com
-
Splice-switching ASO curtails brain calcification Nat. Rev. Drug. Disc. (IF 122.7) Pub Date : 2024-09-09
Discover the world’s best science and medicine | Nature.com
-
PPAR agonists provide new treatment options for inflammatory liver disease Nat. Rev. Drug. Disc. (IF 122.7) Pub Date : 2024-09-09
Discover the world’s best science and medicine | Nature.com
-
RIPTACs expand anticancer target space Nat. Rev. Drug. Disc. (IF 122.7) Pub Date : 2024-09-09
Discover the world’s best science and medicine | Nature.com
-
Organoids identify a role for IL-7 in coeliac disease Nat. Rev. Drug. Disc. (IF 122.7) Pub Date : 2024-09-09
Discover the world’s best science and medicine | Nature.com
-
Understanding anellovirus immune evasion Nat. Rev. Drug. Disc. (IF 122.7) Pub Date : 2024-09-06
Discover the world’s best science and medicine | Nature.com
-
Apolipoprotein L2 inhibitor mitigates fibrosis Nat. Rev. Drug. Disc. (IF 122.7) Pub Date : 2024-09-06
Discover the world’s best science and medicine | Nature.com
-
Targeting the peripheral neural-tumour microenvironment for cancer therapy Nat. Rev. Drug. Disc. (IF 122.7) Pub Date : 2024-09-06 Dan Yaniv, Brandi Mattson, Sebastien Talbot, Frederico O. Gleber-Netto, Moran Amit
-
Protein isoform-centric therapeutics: expanding targets and increasing specificity Nat. Rev. Drug. Disc. (IF 122.7) Pub Date : 2024-09-04 Peter Kjer-Hansen, Tri Giang Phan, Robert J. Weatheritt
-
Engineered parasite delivers proteins to the brain Nat. Rev. Drug. Disc. (IF 122.7) Pub Date : 2024-08-23
Discover the world’s best science and medicine | Nature.com
-
Degrading cell-free DNA to prevent recurrent stroke Nat. Rev. Drug. Disc. (IF 122.7) Pub Date : 2024-08-22
Discover the world’s best science and medicine | Nature.com
更新日期：2024-10-10
Copyright © 2014-2024 北京衮雪科技有限公司 All Rights Reserved
京ICP备11026495号-2
京公网安备 11010802027423号
京公网安备 11010802027423号